Chronic migraine and remote working during COVID-19 lockdown

Abstract

month treatment in reduction of MMD(Graph2). At 3 month there is a reduction of the morning chronotype in favor of the intermediate one(Graph4) and in insomnia. Most common adverse event is constipation, which is observed in 9 patients(10%). No adverse events led to withdraw. ConclusionsOur real-life data confirm the efficacy and safety of erenumab in chronic migraine up to one year treatment with a significant improvement on quality of life. It is the first study that evaluate the effect of Erenumab on sleep: it could be attributed to an improvement in headache or to Erenumab action on CGRP, that is implicated in the mechanism underlying circadian rhythm.

Associação entre comportamento alimentar e hábitos de vida e aumento de crises de migrânea em universitários na pandemia da COVID-19

“…Therefore, in the pandemic period, some changes could be observed in the onset of crises, driven by changes in sleep patterns, physical exercise, changes in diet and water intake, and a possible increase in inflammatory status with weight gain, which is associated with the onset of migraine. 4,5 Therefore, it can be seen that migraine patients were largely affected by these changes.…”